Sacituzumab tirumotecan shows significant clinical benefit in advanced/recurrent endometrial cancer
esmo -
AI Summary: A novel antibody–drug conjugate targeting endometrial tumors produced striking clinical benefits in advanced or recurrent disease, reducing disease progression and cutting mortality risk by roughly one-third while improving progression-free survival. The results have prompted urgent attention from oncologists and regulators as the treatment positions itself as a new option for patients with few alternatives.
Related Stories
Pembrolizumab plus chemotherapy sustains survival in advanced endometrial cancer / 4 months
Neoadjuvant GDFATHER-NEO: visugromab plus nivolumab in MIBC / 2 days
Atirmociclib reduces progression after prior CDK4/6 inhibition in endocrine‑resistant breast cancer / 2 days
Low pCR reported with trastuzumab‑deruxtecan in early breast cancer / 3 days
Merck and Moderna report positive phase‑3 melanoma vaccine results / 2 months
Belzutifan plus lenvatinib outperforms cabozantinib in advanced RCC / 2 months
First patient enrolled in AACR-ADOPT-GEA gastroesophageal cancer trial / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Weight Loss, Health IT, Nutrition, Government Policy and look for the RSS link.
StackHealth Time Machine